

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Immunotech Biopharm Ltd**

**永泰生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6978)**

### **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION SUBSCRIPTION IN AN INVESTMENT FUND**

Reference is made to the announcement of Immunotech Biopharm Ltd (the “**Company**”) dated 6 January 2021 (the “**Announcement**”) in respect of the discloseable transaction relating to the subscription of limited partner interest in Tasly Bioscience Fund, L.P. (the “**Investment Fund**”) and the subscription of interests therein. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board would like to provide the shareholders and potential investors of the Company with further information relating to the Investment Fund as follows:

#### **FURTHER INFORMATION OF THE INVESTMENT FUND**

According to Tasly Bioscience Fund Limited, the General Partner of the Investment Fund, it is an indirect wholly-owned subsidiary of Tasly Holding Group Co., Ltd. (天士力控股集團有限公司) (“**Tasly Holding Group**”). Tasly Holding Group is owned as to 67.08% by Tianjin Tasly Health Industry Investment Group Co., Ltd. (天津天士力大健康產業投資集團有限公司) (“**Tasly Investment**”), an investment company in the PRC with self-owned funds. Tasly Investment is then in turn owned as to 51% by Tianjin Fuhuade Technology Development Co., Ltd.\* (天津富華德科技開發有限公司), a company established in the PRC and principally engaged in the research and development of medical technology and technology consultation services, which is controlled by Mr Yan Kaijing (閆凱境) (“**Mr Yan**”), who is the ultimate beneficial owner of the General Partner of the Investment Fund.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, the General Partner and Mr Yan are third parties independent of the Company and its connected persons.

By order of the Board  
**Immunotech Biopharm Ltd**  
**Tan Zheng**  
*Chairman and executive Director*

Hong Kong, 13 January 2021

*As at the date of this announcement, the Board of the Company comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu and Mr Jung Hyun Chul as executive Directors, Mr Si Xiaobing, Mr Lu Yuan and Mr Li Yuezhong as non-executive Directors, and Mr Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.*